AstraZeneca PLC (AZN) Total Return CAGR:25.21%(TTM)
Over the latest trailing 12-month period, AstraZeneca PLC (AZN)'s total return cagr is +25.21%. The comparable SPY value is +24.09%. Year-to-date total return is +4.97%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, AstraZeneca PLC's Total Return CAGR averages 9.05% over 3 years and 11.47% over 5 years. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of AstraZeneca PLC's investment performance.
AZN Total Return CAGR Chart
AstraZeneca PLC (AZN)
AZN Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 20 quarters.
AZN Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 2180.34 | 2288.64 | +108.30 | +4.97% | +4.97% |
| 2025 | 1579.81 | 2180.34 | +600.53 | +38.01% | +38.01% |
| 2024 | 1598.98 | 1579.81 | -19.17 | -1.20% | -1.20% |
| 2023 | 1586.00 | 1598.98 | +12.99 | +0.82% | +0.82% |
| 2022 | 1316.59 | 1586.00 | +269.41 | +20.46% | +20.46% |
| 2021 | 1116.48 | 1316.59 | +200.11 | +17.92% | +17.92% |
| 2020 | 1084.91 | 1116.48 | +31.58 | +2.91% | +2.91% |
| 2019 | 789.64 | 1084.91 | +295.27 | +37.39% | +37.39% |
| 2018 | 693.25 | 789.64 | +96.39 | +13.90% | +13.90% |
| 2017 | 512.85 | 693.25 | +180.40 | +35.18% | +35.18% |
| 2016 | 616.21 | 512.85 | -103.36 | -16.77% | -16.77% |
| 2015 | 615.80 | 616.21 | +0.41 | +0.07% | +0.07% |
| 2014 | 494.09 | 615.80 | +121.71 | +24.63% | +24.63% |
| 2013 | 374.41 | 494.09 | +119.68 | +31.97% | +31.97% |
| 2012 | 344.86 | 374.41 | +29.55 | +8.57% | +8.57% |
| 2011 | 325.01 | 344.86 | +19.85 | +6.11% | +6.11% |
| 2010 | 313.91 | 325.01 | +11.09 | +3.53% | +3.53% |
| 2009 | 260.60 | 313.91 | +53.31 | +20.46% | +20.46% |
| 2008 | 259.91 | 260.60 | +0.69 | +0.26% | +0.26% |
| 2007 | 313.28 | 259.91 | -53.38 | -17.04% | -17.04% |
| 2006 | 278.11 | 313.28 | +35.17 | +12.65% | +12.65% |
| 2005 | 203.21 | 278.11 | +74.91 | +36.86% | +36.86% |
| 2004 | 260.51 | 203.21 | -57.31 | -22.00% | -22.00% |
| 2003 | 188.39 | 260.51 | +72.12 | +38.28% | +38.28% |
| 2002 | 245.52 | 188.39 | -57.13 | -23.27% | -23.27% |
| 2001 | 266.88 | 245.52 | -21.36 | -8.00% | -8.00% |
| 2000 | 207.44 | 266.88 | +59.44 | +28.65% | +28.65% |
| 1999 | 219.22 | 207.44 | -11.78 | -5.37% | -5.37% |
| 1998 | 172.56 | 219.22 | +46.66 | +27.04% | +27.04% |
| 1997 | 131.02 | 172.56 | +41.54 | +31.70% | +31.70% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 2,289 | -6.0% | +31.5% |
| Q1 2026 | 2,434 | +5.1% | +28.6% |
| Q4 2025 | 2,316 | +25.1% | +44.4% |
| Q3 2025 | 1,852 | +6.4% | -2.6% |
| Q2 2025 | 1,740 | -8.0% | -8.9% |
| Q1 2025 | 1,892 | +18.0% | +17.6% |
| Q4 2024 | 1,604 | -15.6% | +2.9% |
| Q3 2024 | 1,900 | -0.5% | +17.2% |
| Q2 2024 | 1,910 | +18.7% | +12.4% |
| Q1 2024 | 1,609 | +3.2% | -0.1% |
| Q4 2023 | 1,559 | -3.8% | -1.8% |
| Q3 2023 | 1,621 | -4.6% | +28.5% |
| Q2 2023 | 1,700 | +5.6% | +16.1% |
| Q1 2023 | 1,610 | +1.4% | +8.9% |
| Q4 2022 | 1,588 | +25.9% | +18.4% |
| Q3 2022 | 1,262 | -13.9% | -6.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot